fashion -WSS

fashion

author：focus 2025-09-30 17:29:11 - browse：5

Several amyloid plaques forming between neurons in a brain — Amyloid plaques forming between neurons. Adobe

The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest.

The drug, called Leqembi, was developed by Eisai, the Japanese pharmaceutical company, and sold in partnership with Biogen. It previously secured conditional approval in January. The FDA’s decision will broaden patient access to the drug under the Medicare program and is likely to boost sales, even as Leqembi’s benefits and safety risks continue to be a source of debate.

Leqembi’s full, or traditional, approval was supported by results of a large clinical trial in which the drug slowed the rate of cognitive and functional decline by 27% compared to a placebo. Leqembi also beat placebo on a series of secondary measures of Alzheimer’s, and it had a dramatic effect on clearing toxic brain plaques called beta-amyloid, which play a role in the progression of the disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Senate HELP committee spars over health care workforce policies

hotspot

leisure time

WSS

CDC's new outbreak response network to include Northeastern

CDC's new outbreak response network to include Northeastern

Experts study whether long Covid risk adds up with each reinfection

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Hospital chaplains balance Covid safety with patients’ spiritual needs

Emergency workers more likely to restrain Black patients: study

entertainment

fashion

hotspot

In Memoriam: Notable people who died in 2023

A preacher's new calling: Diversifying neuroscience research

Activists slam private health insurers over coverage restrictions

Ukraine and a new approach to mental health in war

Moonlake's readout produced a cash windfall. Risks remain

STAT Virtual Event: JPM Recap, Live!

Heart attack and stroke risk calculators need revising

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Duchenne breakthrough therapy leaves behind pioneering families

Drug for rare kidney disease narrowly misses mark in clinical trial

hotspot

Hearing on Medicare drug price negotiation gets unusually heated

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Medical student insurance fails on mental health care coverage

EpiPen alternative approval delay highlights citizen petition issue

Lasker Awards 2023: Winners in biomedical research

Biotech lab space demand falls sharply

hotspot

Wikipedia

leisure time

explore